BioSpace News Archive

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2022 on Monday, August 15, 2022 after the close of trading on the U.S. financial markets.

Apnimed announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022.

Endologix LLC , a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022.

Fulgent Genetics, Inc. today announced it has launched a test for monkeypox that leverages the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors.

Milestone Scientific Inc. today announced that it has re-engaged Clinical Technology, Inc. (CTI), a leading specialty distributor of medical products in the mid-west and east coast regions of the United States, as a domestic distributor for the CompuFlo® Epidural System.

Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022.

Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“ Aleafia Health ” or the “ Company ”) will announce on August 11 prior to market open its fiscal year 2023 first quarter results for the period ending June 30, 2022.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.